Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2i) is Part of Guideline-Directed Medical Therapy for HFrEF
The correct answer is C: sodium-glucose cotransporter-2 inhibitor, which is now a cornerstone Class I recommendation in guideline-directed medical therapy (GDMT) for heart failure with reduced ejection fraction alongside renin-angiotensin system inhibitors (or ARNi), beta-blockers, and mineralocorticoid receptor antagonists. 1
Core GDMT for HFrEF: The Four Pillars
For this 55-year-old woman with HFrEF (LVEF 30%), the 2022 AHA/ACC/HFSA guidelines explicitly identify SGLT2 inhibitors as foundational therapy 1. The treatment algorithm shows these four medication classes should be initiated simultaneously or sequentially at initial doses without waiting to achieve target dosing before starting the next agent:
- ARNi/ACEi/ARB (renin-angiotensin system modulation)
- Beta-blockers
- Mineralocorticoid receptor antagonists (MRA)
- SGLT2 inhibitors (dapagliflozin or empagliflozin)
Why SGLT2 Inhibitors Are the Answer
SGLT2 inhibitors reduce the combined risk of cardiovascular death or heart failure hospitalization by 26%, decrease recurrent hospitalizations by 25%, and reduce all-cause mortality by 13% in HFrEF patients 2. These benefits occur regardless of diabetes status, making them universally applicable to HFrEF management 3, 2.
The evidence is particularly robust: meta-analysis of EMPEROR-Reduced and DAPA-HF trials involving 8,474 patients demonstrated consistent mortality and morbidity benefits across all clinically relevant subgroups 2. Recent registry data confirms SGLT2 inhibitors are now recognized as essential therapy, though real-world implementation remains suboptimal with only 26-30% of eligible patients receiving them 4.
Why the Other Options Are Incorrect
Vasodilators (Option B): Hydralazine-isosorbide dinitrate has a limited, specific role. It's recommended primarily for African American patients who remain symptomatic despite optimal therapy with ARNi/ACEi, beta-blockers, and MRA 1. For non-African American patients or as first-line therapy, vasodilators are not part of standard GDMT and showed inferior outcomes compared to ACE inhibitors in head-to-head trials 1.
GLP-1 Receptor Agonists (Option A): While emerging evidence suggests semaglutide improves quality of life and exercise capacity in obese HFpEF patients 5, GLP-1 agonists are not currently included in guideline-directed therapy for HFrEF. They may prevent heart failure in diabetic patients but lack established mortality/morbidity benefits in established HFrEF 5.
Calcium Channel Blockers (Option D): These agents are not part of GDMT for HFrEF and may worsen outcomes due to negative inotropic effects, particularly with non-dihydropyridine agents. They have no role in standard HFrEF management.
Clinical Implementation Pitfall
The most common error is delaying SGLT2 inhibitor initiation. Unlike older paradigms requiring sequential uptitration, current guidelines emphasize starting all four foundational therapies early—even simultaneously at low doses—then uptitrating as tolerated 1. Registry data shows only 26% of new HFrEF patients receive SGLT2 inhibitors within 3 months of diagnosis, representing a major care gap 4.
For your patient with new or worsening HFrEF (BNP 1100, LVEF 30%), initiate an SGLT2 inhibitor (dapagliflozin 10 mg daily or empagliflozin 10 mg daily) immediately alongside the other three pillars of GDMT, regardless of diabetes status or renal function (down to eGFR ≥20 mL/min).